Ethan Basch,Amylou Dueck
Ethan Basch
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial [0.03%]
在混合癌症人群中进行的国际多中心、开放性随机对照试验中，使用或不使用欧洲肿瘤研究所患者预后结果数据的CTCAE评估的分级者间信度
Lisa M Wintner,Monika Sztankay,Hikmat Abdel-Razeq et al.
Lisa M Wintner et al.
Background: The Common Terminology Criteria for Adverse Events (CTCAE) is the standard for provider-based rating of adverse events in oncology, but its reliability for symptomatic adverse events is low. Patient-reported o...
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial [0.03%]
卡博替尼联合替莫唑胺治疗不能手术或发生转移的平滑肌肉瘤和其他软组织肉瘤患者：一项多中心单组序贯入组Ⅱ期试验
Varun Monga,Scott Okuno,Brian Van Tine et al.
Varun Monga et al.
Background: The prognosis for patients with unresectable or metastatic soft tissue sarcomas remains poor. Evidence shows that a combination of antiangiogenic agents and chemotherapy inhibit tumour growth. We aimed to inve...
Udani Samarasekera
Udani Samarasekera
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial [0.03%]
帕博利珠单抗联合乐伐替尼治疗复发性妇科透明细胞癌（LARA）：一项多中心、单组、2期试验
Natalie Y L Ngoi,Jung-Yun Lee,Diana Lim et al.
Natalie Y L Ngoi et al.
Background: Combined targeting of angiogenic and immune pathways is an emerging strategy in clear cell carcinomas arising from the gynaecological tract (CCGCs), given the unique molecular and microenvironmental features o...
PFAS in biosolids used in US food supply could pose cancer risk [0.03%]
美国食品供应链中使用的生物固体可能含有致癌的PFAS物质
Elizabeth Gourd
Elizabeth Gourd
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial [0.03%]
一项关于切除的表皮生长因子受体突变型非小细胞肺癌患者术后辅助治疗的研究：奥美替尼疗效与安全性的一项多中心、随机、双盲、安慰剂对照的III期临床试验（ARTS研究）
Liang Zhang,Xiqin Zhang,Lin Wu et al.
Liang Zhang et al.
Background: Patients with resectable non-small-cell lung cancer (NSCLC), particularly those with EGFR mutations, face a high risk of recurrence and mortality post-surgery. Aumolertinib, a third-generation EGFR tyrosine-ki...
Antonio Passaro,Xiuning Le
Antonio Passaro
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial [0.03%]
关于塞利尤单抗治疗来那度胺难治多发性骨髓瘤（CARTITUDE-4）的研究：一项开放标签、多中心、随机、三期试验的总生存期更新分析
Hermann Einsele,Jesús San-Miguel,Binod Dhakal et al.
Hermann Einsele et al.
Background: In CARTITUDE-4, a single infusion of ciltacabtagene autoleucel (cilta-cel) significantly prolonged progression-free survival in patients with lenalidomide-refractory multiple myeloma. We report updated overall...